argenx SE (ARGX) is a Netherlands-headquartered, Nasdaq-listed global immunology company best known for Vyvgart (efgartigimod alfa), an FcRn blocker used to treat autoimmune diseases such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). With the stock trading near $819, the central question for investors is whether ARGX can reach a $1,150 stock price target. That level sits about 40% above the latest verified market price, making it a meaningful but not extreme ambition for a company whose shares have traded between roughly $662 and $1,073 over the past year.
The $1,150 central target reflects a broad collection of current individual analyst targets rather than any single firm's view. Recent figures include Wells Fargo at $1,355, UBS at $1,400, Morgan Stanley at $1,140, Jefferies at $1,215, Piper Sandler at $1,215, H.C. Wainwright at $1,202, Citizens JMP at $1,200, TD Cowen near $1,353, Wedbush at $1,150, Bank of America at $1,136, Oppenheimer and RBC Capital each at $1,100, Truist at $1,095, Evercore ISI at $1,078, and Baird at $823. The spread from about $823 to $1,415 is unusually wide, and it underscores how differently analysts weigh growth potential against an already-rich valuation.
The analyst consensus leans strongly bullish, with most ratings at Buy or equivalent. Yet the tone has grown more cautious in places: Baird downgraded ARGX to Neutral in December 2025 on stretched valuation, and Deutsche Bank moved to a Hold stance in August 2026 even while acknowledging Vyvgart's momentum. By contrast, UBS upgraded the stock to Buy in late August and raised its target to $1,400, citing pipeline breadth. This split—bullish on the science, wary of the price—is the defining feature of current coverage.
ARGX last closed at $819.14, down about 3% on the day and roughly 17% over the prior month, after peaking near its 52-week high of $1,072.75 in early September 2026. Reaching $1,150 would require a gain of about 40%—a substantial move that would also carry the stock decisively above its prior record high. That is possible only if the company converts its pipeline promise into sustained revenue growth and investors accept a higher valuation multiple. The path runs through Vyvgart's expansion into new indications, the integration of the Forte Biosciences acquisition, and continued execution under a newly announced CEO transition from founder Tim Van Hauwermeiren to Karen Massey.
The fundamental case rests on Vyvgart becoming a true platform drug. The franchise already generates more than $5 billion in annual global revenue, and analysts have raised targets repeatedly following positive Phase 3 ALKIVIA data in autoimmune myositis, which de-risked expansion into rheumatology. Recent readouts in seronegative gMG and ocular MG, plus the planned acquisition of Forte Biosciences and its anti-CD122 antibody FB102 for celiac disease, broaden the opportunity. Improving profitability—net income has swung firmly positive—supports a growth narrative that bullish analysts argue is still underpriced relative to large-cap immunology peers.
The principal obstacle is valuation. At a forward P/E (price-to-earnings ratio) near 28, the shares already embed substantial optimism, and several analysts have said they are "not chasing" the stock at current levels. The discontinuation of the Phase 3 UNITY trial in Sjögren's disease after a futility analysis is a reminder that not every indication will succeed. Competition in autoimmune biologics is intensifying, and any delay in regulatory approval for myositis, slower launch traction, or a guidance cut could compress the multiple quickly. A sustained pullback from the September peak shows how sensitive the stock is to pipeline and valuation news.
Technically, $1,072.75—the September 2026 record high—stands as the key resistance level that must first be reclaimed before a move toward $1,150 becomes plausible. The $1,000 round-number mark also looms as a psychological barrier. On the downside, the 52-week low of $661.85 set in March 2026 marks a major support zone, with the current level around $819 well above it. A sustained close back above $1,000 would signal renewed momentum, while a break below the mid-$800s could delay any recovery toward the target.
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms apply different assumptions about risk-adjusted revenue and multiples. The next major catalyst is the company's third-quarter earnings report, expected around October 22, 2026, which will be closely watched for Vyvgart revenue, guidance, and any update on the CEO transition. Investors should also track regulatory progress on myositis and dermatomyositis, additional clinical readouts in ocular MG and ITP (immune thrombocytopenia), the closing of the Forte Biosciences deal, and any further analyst rating changes.
For traders monitoring whether ARGX can build momentum toward a higher price target, Tickeron's AI Daily Buy/Sell Signals offer a data-driven complement to fundamental research. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. These signals can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening. Explore the AI Daily Buy/Sell Signals to see how automated analysis fits into your own decision-making process.
Can ARGX reach $1,150? The answer depends less on the science—which remains broadly encouraging—and more on whether investors will pay an even higher multiple for it. A roughly 40% advance from $819 is substantial, and it would require reclaiming the prior record high near $1,073 first. The bullish case rests on Vyvgart's expanding franchise, positive myositis data, and a deeper pipeline, while the bearish case points to stretched valuation, clinical setbacks such as the UNITY discontinuation, and rising competition. With analyst targets spanning roughly $823 to $1,415, there is no consensus that the stock is either cheap or fully valued. Investors should watch earnings, regulatory milestones, and valuation signals before drawing any conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with AXON. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
|---|---|---|---|---|
| ARGX | 100% | +3.63% | ||
| AXON - ARGX | 40% Loosely correlated | -18.18% | ||
| ARRY - ARGX | 36% Loosely correlated | +10.47% | ||
| ONC - ARGX | 36% Loosely correlated | +5.09% | ||
| IMCR - ARGX | 34% Loosely correlated | +9.12% | ||
| VRTX - ARGX | 34% Loosely correlated | +0.85% | ||
More | ||||